Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Schizoaffective Disorder: full-pipeline trial registry
31 of 105 indexed Schizoaffective Disorder trials are currently recruiting.
Corpus placement: #125 of 28,707 conditions by registered trial count.
105 US clinical trials · 31 currently recruiting · #125 of 28,707 conditions by registered trial count
Schizoaffective Disorder: 105 US clinical trials tracked, 31 recruiting.
Schizoaffective Disorder is the subject of 105 registered US clinical trials on ClinicalTrials.gov, 31 of them currently open to new participants. 20 are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most active sponsor is University of Maryland, Baltimore, running 8 of these trials.
Enrollment posture brief
Registry condition schizoaffective-disorder
OPEN 31 | RECR 30% | LATE 20 | EARLY 21 | RANK #125 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Emphysema (30% recruiting · 27 trials)
Schizoaffective Disorder lists 31 open slots (30% of 105 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Schizoaffective Disorder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Schizoaffective Disorder is recruiting below its size-band peers.
31 of 105 indexed trials (29.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Schizoaffective Disorder trials is spread across many organizations.
University of Maryland, Baltimore accounts for 8 of 105 trials (7.6%). 56 distinct sponsors appear on at least one study for this condition label.
-
Most Schizoaffective Disorder trials plan to enrol fewer than 100 people.
Median target enrolment is 67 among the 104 trials that report a genuine target (sentinel values excluded). 66 of those (63.5%) plan for fewer than 100 participants.
-
Schizoaffective Disorder research is mostly interventional.
99 interventional and 6 observational studies make up this index (94.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
105 total, page 1 of 3
CLOZAPINE Response in Biotype-1
University of Texas Southwestern Medical Center
NCT04580134
Enhanced Coordinated Specialty Care for Early Psychosis
Mclean Hospital
NCT06071858
Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
Beth Israel Deaconess Medical Center
NCT06740383
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
New York State Psychiatric Institute
NCT05208190
Randomized Clinical Trial of iTEST: A Blended Intervention Targeting Introspective Accuracy
University of California, San Diego
NCT07098169
Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia
Vishwajit Nimgaonkar, MD PhD
NCT03794076
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
BioXcel Therapeutics
NCT05025605
Context-Aware Mobile Intervention for Social Recovery in Serious Mental Illness (R33)
University of California, San Diego
NCT06865937
Non-invasive Brain Stimulation Using Tdcs of the Third (of Many) Visual Pathways
Nathan Kline Institute for Psychiatric Research
NCT07469384
Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders
University of Pittsburgh
NCT07043803
Anticholinergic Deprescription in Schizophrenia
Deepak K. Sarpal, M.D.
NCT06562608
Improving Cognition Through Telehealth Aerobic Exercise and Cognitive Training After a First Schizophrenia Episode
University of California, Los Angeles
NCT05890183
iTBS to Enhance Social Cognition in People With Psychosis
Northwell Health
NCT06118268
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
Mayo Clinic
NCT07213466
Cerebellar Modulation of Cognition in Psychosis
Mclean Hospital
NCT06107764
Visual Perception in Schizophrenia
University of Rochester
NCT06911931
Effectiveness of Motivation Skills Training (MST)
Columbia University
NCT05805397
Enhancing Rehabilitation for Veterans With Serious Mental Illness
VA Office of Research and Development
NCT06586164
Decision-Making in Schizophrenia: A Combined Neuroimaging and Experience Sampling Study
Rutgers, The State University of New Jersey
NCT06745479
Cognitive Training for Emotion Regulation in Psychotic Disorders
University of Georgia
NCT04414215
Using Transcranial Magnetic Stimulation (TMS) to Understand Hallucinations in Schizophrenia
Mclean Hospital
NCT05343598
Prebiotic Treatment in People With Schizophrenia
University of Maryland, Baltimore
NCT05527210
Acetazolamide for Treatment Resistant Schizophrenia
Vishwajit Nimgaonkar, MD PhD
NCT04887792
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
Temple University
NCT06336616
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Neurocrine Biosciences
NCT07105111
Ketogenic and Nutritional Interventions for First Episode Bipolar Disorder
Mclean Hospital
NCT06221852
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
University of Massachusetts, Worcester
NCT06174116
Exercise and Olanzapine-samidorphan
New York State Psychiatric Institute
NCT06740890
Accelerated Transcranial Magnetic Stimulation for People With Schizophrenia Treated With Clozapine
Deepak K. Sarpal, M.D.
NCT06003036
Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy
Michigan State University
NCT06529029
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
Corporal Michael J. Crescenz VA Medical Center
NCT03495024
Database Registry for Neural Network Biomarkers in Psychosis
University of Texas Southwestern Medical Center
NCT01409109
EPI-MINN: Targeting Cognition and Motivation - National
University of Minnesota
NCT05877716
Ketogenic Diet in People With Schizophrenia
University of Maryland, Baltimore
NCT05968638
Optimizing CBSST With Executive Function Training for Schizophrenia
University of California, San Diego
NCT06251193
Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder
BioXcel Therapeutics
NCT07116694
Young Adults With Violent Behavior During Early Psychosis (Aim 2)
Columbia University
NCT05756855
Genetic Study of Schizophrenia
National Institute of Mental Health (NIMH)
NCT00001486
Neural Oscillations as Genetic and Functional Biomarkers in Normal and Disease States
University of Maryland, Baltimore
NCT01425671
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
Janssen Scientific Affairs
NCT01193153
Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
Eli Lilly and Company
NCT00100776
Improving Care and Reducing Cost Study
Northwell Health
NCT02364544
Cognitive Skills Training Using Computer for Patients With Severe Mental Illness
Nathan Kline Institute for Psychiatric Research
NCT01036282
Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
NCT00412373
Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography
National Institute of Mental Health (NIMH)
NCT00942981
A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents
Sumitomo Pharma America
NCT01143077
The Appeal and Impact of E-cigarettes in Smokers With SMI
Dartmouth-Hitchcock Medical Center
NCT03050853
The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness.
US Department of Veterans Affairs
NCT00466323
Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder
Otsuka Pharmaceutical Development & Commercialization
NCT01423916
Comparing Mobile Health (mHealth) and Clinic-Based Self-Management Interventions for Serious Mental Illness
Dartmouth-Hitchcock Medical Center
NCT02421965
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 10 |
| Phase 2 | 11 |
| Phase 3 | 4 |
| Phase 4 | 16 |
Top Sponsors
Named interventions
Most-linked intervention names on Schizoaffective Disorder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Schizoaffective Disorder trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Schizoaffective Disorder page
105 registered trials, 31 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 31 Schizoaffective Disorder trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Maryland, Baltimore sponsors the most Schizoaffective Disorder trials on record, review their full trial history before evaluating a specific study. See University of Maryland, Baltimore's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Schizoaffective Disorder condition card totals 105 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.